CytoMed Therapeutics Limited
GDTC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.46 | 4.99 | -0.38 | 1.51 |
| FCF Yield | -7.67% | -5.22% | -4.41% | -6.14% |
| EV / EBITDA | -20.07 | -15.53 | -30.71 | -27.00 |
| Quality | ||||
| ROIC | -37.73% | -36.11% | -47.32% | -32.24% |
| Gross Margin | 100.72% | 131.44% | 0.00% | 96.92% |
| Cash Conversion Ratio | 1.08 | 0.85 | 0.45 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | – | 51.13% | -100.00% | – |
| Free Cash Flow Growth | -10.64% | -94.59% | 17.87% | -105.44% |
| Safety | ||||
| Net Debt / EBITDA | 1.84 | 2.20 | -1.80 | -0.53 |
| Interest Coverage | -172.79 | -83.79 | -18.69 | -15.97 |
| Efficiency | ||||
| Inventory Turnover | 0.04 | 0.01 | 0.19 | 0.01 |
| Cash Conversion Cycle | 9,503.98 | 64,064.48 | 1,888.42 | 40,264.57 |